Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVITREALStandard

SYFOVRE

PEGCETACOPLAN

Standard Dose
15MG/0.1ML (15MG/0.1ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview SYFOVRE is listed in Drugs@FDA under application 217171 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient PEGCETACOPLAN Form and strength SOLUTION;INTRAVITREAL - 15MG/0.1ML (15MG/0.1ML) Sponsor APELLIS PHARMS Submission history Latest submission status date: 2025-03-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview SYFOVRE is listed in Drugs@FDA under application 217171 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient PEGCETACOPLAN Form and strength SOLUTION;INTRAVITREAL - 15MG/0.1ML (15MG/0.1ML) Sponsor APELLIS PHARMS Submission history Latest submission status date: 2025-03-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.